Companies › Inhibikase Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular; next expected readout Jun 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IKT-001 TIE2 receptor agonist | – | Phase 3 | Pulmonary Arterial Hypertension | Jun 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07365332 | IKT-001 | Phase 3 | Pulmonary Arterial Hypertension | Cardiovascular | Jun 2029 |
Cash and short-term investments of $159m on 2026-06-30; operating cash outflow about $50m a year; runway about 38 months at that burn, to Sep 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Theravance Biopharma Boston Scientific Braveheart Bio CeleCor Therapeutics MedTrace Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.